The screen also showed that the dual mTOR/PI3K inhibitor BEZ-235 sensitized both DasR and PazR which recapitulates the findings of a recent report on the use of this drug to overcome pazopanib resistance in patient-derived soft tissue sarcoma cells [54]. This evidence concerns the gene MTOR and soft tissue sarcoma.